Vyluma is a private biopharmaceutical company specializing in ophthalmic pharmaceutical solutions. With a commitment to developing innovative treatments for global unmet needs, Vyluma focuses on improving the quality of life for patients of all ages. Their team of experts, including scientific advisors and industry leaders, work diligently to develop and commercialize transformative therapeutics to preserve patients' vision.

Vyluma's pipeline programs aim to preserve visual function, prevent blindness, and restore patients' quality of life. One of their leading candidates, NVK002, is an eye drop designed to slow the progression of myopia in children. If approved, it will be the first pharmaceutical treatment for myopia.

Additionally, Vyluma is developing NVK029, an alternative therapy for presbyopia. This product could provide an accessible solution for the more than 110 million adults in the United States affected by this condition. Vyluma's innovative approach also extends to addressing night vision disturbance.

Through their NVK031 program, they have successfully reduced symptoms of glare by 1mm-2mm in their proof-of-concept clinical study. Committed to patient-focused solutions, Vyluma is dedicated to improving lives by enhancing vision and enabling individuals to enjoy life's little details